AGM Presentation

November 12, 2015August 16, 2022 Kerry Rowe

2015_11_13 Prana AGM Presentation 2

2015

Post navigation

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM Presentation

Related Posts

Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare

Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA

Prana Provides Update on PBT2 Alzheimer’s Disease Extension trial